The Croatian Phase I and II clinical trials for inflammatory bowel disease conducted in the 1990s by pharmaceutical company Pliva claimed safety with no significant toxicity, though complete peer-reviewed data never appeared in scientific literature beyond conference abstracts
Mann, T., Gerwat, W., Batzer, J., Eggers, K., Scherner, C., Wenck, H., Stb, F., Hearing, V
Its ability to regulate actin, a critical component of cell structure and movement, makes it uniquely suited for studies involving injury recovery and tissue remodeling
Conventional treatments address either the bone or the surrounding soft tissue, rarely both simultaneously
That sounds fake, but it's got main character energy